Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known

Journal of Thoracic Oncology

Volumn 1, Issue 5, 2006, Pages 398-402

  Sekine, Ikuo ^a   Takada, Minoru ^b   Nokihara, Hiroshi ^a   Yamamoto, Seiichiro ^c   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c Research Center for Cancer Prevention and Screening   (Japan)

Author keywords

Effectiveness; Efficacy; Large scale trials; Lung cancer; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL DERIVATIVE; GEFITINIB; LEFLUNOMIDE; OXALIPLATIN; SORIVUDINE; VASCULOTROPIN INHIBITOR; QUINAZOLINE DERIVATIVE;

BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SCREENING; EXTERNAL VALIDITY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNAL VALIDITY; INTERNET; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MEDICAL EDUCATION; METASTASIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPTIC SHOCK; SKULL IRRADIATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTICLE; LUNG TUMOR; META ANALYSIS; METHODOLOGY; STANDARD;

CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; QUINAZOLINES; RESEARCH DESIGN;

EID: 34247270263     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200606000-00002     Document Type: Review

References (29)

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-72.
2. Knottnerus JA, Dinant GJ. Medicine based evidence, a prerequisite for evidence based medicine. BMJ 1997;315:1109-1110.
3. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?' Lancet 2006;365:82-93.
4. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2006;365:176-186.
5. Thompson SG, Higgins JP. Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? Lancet 2006;365:341-346.
6. Egger M, Smith GD. Meta-analysis. Potentials and promise. BMJ 1997;315:1371-1374.
7. Nash JM, McCrory D, Nicholson RA, et al. Efficacy and effectiveness approaches in behavioral treatment trials. Headache. 2006;45:507-512.
8. Bausewein C, Higginson IJ. Appropriate methods to assess the effectiveness and efficacy of treatments or interventions to control cancer pain. J Palliat Med 2004;7:423-430.
9. Piantadosi S. Clinical Trials. New York: John Wiley & Sons , Inc., 1997.
10. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
11. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004;5:489-496.
12. Aventis Pharma Japan. Postmarketing surveillance of leflunomide tablet. Available at: http://www.aventis.co.jp/arava/aravad/index.html, 2005.
13. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
14. AstraZeneca. Results and discussion on IRESSA Tablet 250 prospective survey. Available at: http://www.mhlw.go.jp/shingi/2005/01/s0120-4. html, 2004.
15. Sandler A, Gray R, Brahmer J, et al. A randomized phase III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer. Proc ASCO 2006;23:2s.
16. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
17. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060.
18. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997;89:1782-1788.
19. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
20. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
21. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
22. Sekine I, Fukuda H, Kunitoh H, et al. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998;28:463-473.
23. Sekine I, Yamamoto N, Kunitoh H, et al. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 2004;30:359-368.
24. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2006;23:9113-9119.
25. Paul J, Seib R, Prescott T. The Internet and clinical trials: background, online resources, examples and issues. J Med Internet Res 2006;7:e5.
26. University Hospital Medical Information Network. Available at: http://www.umin.ac.jp/, 2005.
27. Meyerson LJ, Wiens BL, LaVange LM, et al. Quality control of oncology clinical trials. Hematol Oncol Clin North Am 2000;14:953-971.
28. Marinus A. Quality assurance in EORTC clinical trials. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;4(38 suppl):S159-S161.
29. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998;317:465-468.